TOP TEN perturbations for 39800_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39800_s_at
Selected probe(set): 201145_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39800_s_at (201145_at) across 6674 perturbations tested by GENEVESTIGATOR:

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):1.7799044
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.7543306
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

glioma study 16 (BS-149) / normal astrocyte sample

Relative Expression (log2-ratio):1.667161
Number of Samples:2 / 3
Experimental glioma study 16 (BS-149)
Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

engineered skin substitute study 2 (early) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):-1.6425533
Number of Samples:6 / 2
Experimental engineered skin substitute study 2 (early)
Human skin substitutes tissue samples collected after 3 and 7 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

sirolimus study 6 (light) / sirolimus study 6 (heavy)

Relative Expression (log2-ratio):1.6201591
Number of Samples:3 / 3
Experimental sirolimus study 6 (light)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:
Control sirolimus study 6 (heavy)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.6161785
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):-1.6050596
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.4847136
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.4367409
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

influenza virus study 11 (A/H5N3) / influenza virus study 9 (A/H5N2)

Relative Expression (log2-ratio):-1.3962221
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.